A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer.

Gruenwald, I E; Stein, A; Rashcovitsky, R; Shifroni, G; Lurie, A

Gruenwald, I E; Stein, A; Rashcovitsky, R; Shifroni, G; Lurie, A.

Affiliation

Gruenwald IE; Department of Urology, Carmel Medical Center, Haifa, Israel.

J Urol ; 157(2): 487-91, 1997 Feb.

Article in En | MEDLINE | ID: mdl-8996340

Subject(s)

Adjuvants, Immunologic/administration & dosage; BCG Vaccine/administration & dosage; Carcinoma, Transitional Cell/prevention & control; Neoplasm Recurrence, Local/prevention & control; Urinary Bladder Neoplasms/prevention & control; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell/secondary; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Time Factors; Urinary Bladder Neoplasms/pathology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / BCG Vaccine / Carcinoma, Transitional Cell / Adjuvants, Immunologic / Neoplasm Recurrence, Local Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Urol Year: 1997 Document type: Article Affiliation country: Israel Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links